Kunimasa, Kei

Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor: Comparison between T790M mutation‐positive and mutation‐negative populations

Hata, A., Katakami, N., Yoshioka, H., Takeshita, J., Tanaka, K., Nanjo, S., Fujita, S., Kaji, R., Imai, Y., Monden, K., et al. (2013) · Cancer

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 178

The ligand Sas and its receptor PTP10D drive tumour-suppressive cell competition

Yamamoto, M., Ohsawa, S., Kunimasa, K., & Igaki, T. (2017) · Nature

Developmental Biology and Gene RegulationHippo pathway signaling and YAP/TAZ

Cited by 157

AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells

Morimoto, K., Yamada, T., Hirai, S., Katayama, Y., Fukui, S., Sawada, R., Tachibana, Y., Matsui, Y., Nakamura, R., Ishida, M., et al. (2024) · Cancer Letters

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 20

Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab

Tamiya, M., Kunimasa, K., Nishino, K., Matsumoto, S., Kawachi, H., Kuno, K., Inoue, T., Kuhara, H., Imamura, F., Goto, K., et al. (2021) · Investigational New Drugs

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 5